Considering the ability of biNV-IL-15 to stimulate antitumor immunity, we constructed the cancer resection model to validate the anti-recurrence effects of biomimetic nanovaccine-mediated IL-15 self-transpresentation (Fig. 7a). The gene discussed is IL15; the disease is cancer.